Rituximab单药与联合rhTPO治疗免疫性血小板减少症对照研究.docVIP

Rituximab单药与联合rhTPO治疗免疫性血小板减少症对照研究 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：Rituximab单药与联合rhTPO治疗免疫性血小板减少症对照研究 1 1 资料与方法 3 2 结果 4 文2：舍曲林联合EMDR治疗抑郁症对照研究 6 1 对象与方法 6 2 结果 8 3 讨论 9 参考文摘引言： 9 原创性声明（模板） 11 文章致谢（模板） 11 正文 Rituximab单药与联合rhTPO治疗免疫性血小板减少症对照研究 文1：Rituximab单药与联合rhTPO治疗免疫性血小板减少症对照研究 [Abstract] Objective To compare the effects of Rituximab single use and combination of Rituximab and rhTPO （recombinant human thrombopoietin） in treatment of immune thrombocytopenia（ITP）. Methods 40 ITP patients treated in our hospital from January to December 2015 were selected and divided according to their treatment patter into LD-RTX single use group （20 cases） and LD-RTX plus rhTPO group （20 cases）. The standard dose of Rituximab （RTX） was 375 mg/m2/week for 4 weeks. RhTPO was a thrombopoietin receptor stimulant and its dose was 300U/d/kg， once daily for 14 days continuously， which was stopped when the count of platelets was 100×109/L or absolute value of platelets was ≥50×109/L. The following paramete were compared including overall respoe rate， mortality， differences in oet time， maintain time and safety. Results （1） The overall respoe rate was significantly higer in the LD-RTX plus rhTPO group （%） than in the LD-RTX single use group （%） （P）； （2） The mortality was significantly lower in the LD-RTX plus rhTPO group （0） than in the LD-RTX single use group （%） （P）； （3） The oet time was significantly shorter and the maintain time was significantly longer in the LD-RTX plus rhTPO group[（±）d，（±）d] than in the LD-RTX single use group[（±）d，（±） d] （P）； （4） There was no severe side effect in either group. Conclusion Rituximab single use and combination of Rituximab and rhTPO can both achieve some treatment effects， while compared with single use， the combination of Rituximab and rhTPO can improve the efficacy and shorten the treatment coue， with longer maintain time of drug effects， which， therefore， is a safe and effective treatment option for patients wi